Technology
Health
Biotechnology

Cue Biopharma

$7.34
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.61 (-7.67%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Cue Biopharma and other stocks, options, ETFs, and crypto commission-free!

About

Cue Biopharma, Inc. Common Stock, also called Cue Biopharma, is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Read More Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.

Employees
46
Headquarters
Cambridge, Massachusetts
Founded
2014
Market Cap
164.54M
Price-Earnings Ratio
Dividend Yield
Average Volume
95.28K
High Today
$8.00
Low Today
$6.75
Open Price
$7.99
Volume
69.10K
52 Week High
$16.24
52 Week Low
$4.16

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Pharmaceutical
2018 IPO
US
North America

News

Simply Wall StMar 13

Do Insiders Own Shares In Cue Biopharma, Inc. (NASDAQ:CUE)?

A look at the shareholders of Cue Biopharma, Inc. (NASDAQ:CUE) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Warren Buffett said that he likes ‘a business with enduring competitive advantages that is run by able and owner-oriented people’. So it’s nice to see some insider ownership, because it may suggest that management is owner-oriented. Cue Biopharma is a smaller...

22
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.